◼ Archived
Business
🔮 fades ✓
MapLight shares sink on mixed ph. 2 schizophrenia readout
MapLight Therapeutics stock plummeted 73% following mixed phase 2 trial data for its schizophrenia candidate, ML-007C-MA.
Biotech
36 independently checked trend briefs about this subject, newest first.
What this Biotech timeline shows
headlinez.news detected 36 source-qualified news clusters connected to Biotech between June 23, 2026 and July 27, 2026. They span 5 newsroom categories and average 6.8 independent sources per brief.
This hub includes only briefs supported by at least four sources and passed by the site's verification gate. Raw or weak detections may exist but are excluded here. Topic matching is based on the entities and themes recorded with each brief; open a card to inspect its source links, publication time, verification label and velocity history. Read the methodology and editorial policy for the full rules.
◼ Archived
Business
🔮 holds ✗
Argenx to Buy Forte Biosciences for $2.2 Billion
A $2.2 billion acquisition agreement marks a significant shift in the immunology market, as Argenx moves to absorb Forte Biosciences.
◼ Archived
Business
🔮 fades ✓
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics faces market volatility and legal investigations following the release of FDA staff documents regarding its therapy, Deramiocel.
◼ Archived
Science
🔮 fades ✓
Precise DNA base editing using AlphaFold3-based contact modelling
Researchers are utilizing AlphaFold3-based contact modelling to redesign gene-editing proteins, aiming to improve safety in CRISPR applications.
◼ Archived
Business
🔮 holds ✗
Why Arrowhead Shot Sky-High, While Chief Rival Ionis Toppled
Arrowhead Pharmaceuticals stock reaches five-year highs following successful Phase 3 trial results, while shares of competitor Ionis decline.
◼ Archived
Business
🔮 fades ✓
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
Tempus AI moves to acquire cancer-tech firm Personalis in a high-stakes stock deal, triggering an immediate downturn in share prices for both companies.
◼ Archived
Business
🔮 fades ✓
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits
Celcuity shares declined by 12.6% despite the company receiving its first FDA approval for a breast cancer treatment.
◼ Archived
Business
🔮 fades ✓
Kalshi Will Offer Sports-Style Betting on Drug Trial Results
Kalshi has introduced new prediction markets that allow users to place wagers on the outcomes of clinical trials and pending FDA drug decisions.
◼ Archived
Business
🔮 holds ✗
Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors
Q32 Bio shares surge following the release of 36-week clinical trial data for its alopecia areata treatment, bempikibart.
◼ Archived
Business
🔮 fades ✓
FDA releases 14 drug rejection letters after 3-month pause
The FDA has resumed the public release of drug rejection letters, issuing 14 new Complete Response Letters following a three-month operational pause.
◼ Archived
Business
🔮 fades ✗
Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector
The FDA has granted approval for Sanofi’s Sarclisa, marking the first time a cancer medication has been cleared for delivery via an on-body injector.
◼ Archived
Technology
🔮 fades ✓
Which ‘AI scientist’ suits your lab? A guide for the perplexed
Anthropic has released a new research workbench, sparking industry discussion on the practical integration of AI tools within laboratory environments.
◼ Archived
Business
🔮 fades ✓
'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive
American biopharma companies are increasing operational secrecy as competition with China’s expanding bioeconomy intensifies.
◼ Archived
Business
🔮 fades ✓
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Novo Nordisk has entered a partnership with Vivani to develop a long-acting semaglutide implant designed for extended weight loss management.
◼ Archived
Business
🔮 holds ✓
FDA approves Vera Therapeutics kidney disease treatment
The FDA has granted accelerated approval to Vera Therapeutics for its new kidney disease drug, Trutakna, targeting primary IgA Nephropathy.
◼ Archived
Health
🔮 fades ✗
Brain tumors: New vaccine offers patients hope for more time
A personalized cancer vaccine targeting glioblastoma mutations enters clinical trials, showing potential for extended patient survival.
◼ Archived
Business
🔮 fades ✗
Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics
Vertex Pharmaceuticals announces a $10 billion acquisition of Crinetics Pharmaceuticals, marking its largest deal to date and an entry into endocrinology.
◼ Archived
Business
🔮 fades ✓
MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization
MeiraGTx has secured a multi-million dollar funding package led by Oberland Capital to support the commercialization of two gene therapies.
◼ Archived
Business
🔮 fades ✓
Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis has announced a deal to acquire U.K.-based cancer biotech Myricx Bio in a transaction valued at up to $1.5 billion.
◼ Archived
Business
🔮 fades ✗
Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles
Vertex Pharmaceuticals has announced a $10 billion acquisition of Crinetics, signaling a significant shift in the biopharma landscape.
◼ Archived
World
🔮 fades ✓
Researchers Built a Scuba Suit for Cyborg Cockroaches
Scientists turn insects into underwater explorers with a 3D-printed 'diving suit'—blurring bioengineering and robotics
◼ Archived
Business
🔮 fades ✗
AI company Anthropic announces it will begin developing drugs of its own
An AI lab is now designing drugs—directly challenging Big Pharma’s profit-driven priorities.
◼ Archived
Business
🔮 fades ✓
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Biotech IPO test: Scribe Therapeutics targets $75M valuation amid early-stage investor scrutiny
◼ Archived
Business
🔮 fades ✓
French biotech stock soars 34% after new data on experimental medicine
Shares of French biotech firm Abivax have surged following the release of new clinical safety data regarding its experimental ulcerative colitis medication.
◼ Archived
Business
🔮 fades ✗
FDA’s top gene therapy regulator is leaving his role
Leadership transitions at the FDA coincide with a significant regulatory rejection for Unicycive Therapeutics.
◼ Archived
Business
🔮 fades ✓
Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion
Ipsen’s $1.75B bid for Kartos Therapeutics reshapes blood cancer drug development—with a twist on the deal’s structure
◼ Archived
Business
🔮 fades ✓
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases
Talawar Therapeutics is set to become a publicly traded company following a definitive business combination agreement with JATT II Acquisition Corp.
◼ Archived
Business
🔮 fades ✓
Stock Market Today: Indexes Mixed; S&P 500 Barely Holds This Significant Level (Live Coverage)
Moderna shares rally on new autoimmune research developments as the broader S&P 500 navigates mixed market sentiment.
◼ Archived
Health
🔮 fades ✓
BIO 2026: How a gut feeling transformed cancer treatment forever
Recent reports from BIO 2026 highlight a significant shift in cancer research toward engineered immune cell therapies and specialized engagement strategies.
◼ Archived
Health
🔮 fades ✓
Silicon Valley's longevity drug obsession is facing its first real reality check
Silicon Valley’s pursuit of longevity drugs faces critical scrutiny as experts question the efficacy of current anti-aging interventions.
◼ Archived
Business
🔮 fades ✓
ROBERT F. KENNEDY JR.: The future of medicine should be built in America
Debate intensifies over U.S. and China biotech competition and domestic manufacturing reliance.
◼ Archived
Business
🔮 fades ✓
AbbVie inks $10.9B Apogee buyout to bag eczema prospect
AbbVie’s $10.9B bid for Apogee Therapeutics signals a high-stakes bet on next-gen autoimmune treatments—including a potential Dupixent rival.
◼ Archived
Business
🔮 holds ✗
HHS Launches Unprecedented Department-Wide Effort to Restore American Leadership in Clinical Trials
The Department of Health and Human Services has initiated a wide-ranging effort to accelerate clinical trials and reclaim American leadership in biotech.
◼ Archived
Business
🔮 fades ✓
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer’s experimental lung cancer drug sigvotatug vedotin has failed to meet its primary objective in a late-stage clinical trial.
◼ Archived
Business
🔮 fades ✓
AbbVie sharpens immunology focus with $10.9 billion Apogee deal
AbbVie’s $10.9B bid for Apogee Therapeutics reshapes biotech M&A landscape overnight
◼ Archived
Business
🔮 fades ✓
Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers
Gene therapy pioneer Sangamo Therapeutics files for bankruptcy, with Lilly and Astellas racing to acquire its assets